Figure S8 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

Le résumé fourni par la source

SALL4 induction in cancer cell by 5-azacytidine modulates SALL4-TCR T cells activation. (A) Expression of SALL4 detected by qRT-PCR (top) and Western blotting (bottom) (Sall4 Antibody (G-3): sc-166033 Santa Cruz) for MDA-MB231 treated with 5-azacytidine (5-aza) (2µM) for 72h and 6 days. (B) Degranulation (CD107a) stainings assessed by flow cytometry comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with MDA-MB231 treated 72h and 6 Days with 5-Aza. T cells were cocultured for 5h at E:T ratio 1:50 for n=3 different HDs, mean ±SEM. Anti-HLA-A2 (BB7.2) were used for specific reactivity controls. Statistics were calculated using ANOVA test, *p<0.05, ***p<0.001. (C) Relative mRNA expression levels of SALL4 in cancer cell lines pretreated or not with 5-aza (2µM) for 72h. (D) Intracellular TNF-α staining assessed by flow cytometry analysis comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with cancer cell lines treated 48h before the coculture with IFN-γ (200UI/mL) and 72 h with 5-aza (2µM) or not. T cells were cocultured for 16h at E:T ratio 1:20. (E) Anti-MHC-I (W6/32) or isotype antibody were used for specific reactivity controls. Cell lines were not treated prior the coculture. HeLa, A2780 and HUH-7 were transduced to express HLA-A2.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.